U.S. DNA Synthesis Market Size To Reach $4.62 Billion By 2033

July 2025 | Report Format: Electronic (PDF)

U.S. DNA Synthesis Market Growth & Trends

The U.S. DNA synthesis market size is projected to reach USD 4.62 billion by 2033, growing at a CAGR of 15.93% from 2025 to 2033, according to a new report by Grand View Research, Inc. The U.S. DNA synthesis market is growing quickly, driven by the increasing need for customized genetic material to support advances in biomedical research, therapeutic development, and synthetic biology. As areas like gene editing, personalized medicine, and molecular diagnostics expand, DNA synthesis has become a key technology that allows researchers and developers to produce precise, high-quality DNA sequences tailored to specific uses. The rising use of CRISPR, mRNA-based therapies, and genetic screening further speeds up the market's growth.

Technological advancements, including chip-based and enzymatic synthesis, transform traditional DNA manufacturing by enabling faster, more scalable, and cost-efficient production. Simultaneously, the integration of AI and automation tools streamlines design, error correction, and sequence optimization, significantly reducing development timelines and boosting accuracy. These innovations are essential for applications like gene therapy, vaccine production, and synthetic biology, which have high demands for rapid prototyping and iteration.

The market's growth is also driven by increasing research activities across academic, pharmaceutical, and contract research sectors. Biopharmaceutical companies and diagnostics developers depend more on high-throughput, custom DNA synthesis services to support drug discovery, biomarker identification, and cell engineering workflows. The move toward outsourced development and manufacturing (CDMO) partnerships further boosts market expansion, as companies seek flexible and scalable synthesis solutions that meet changing regulatory standards.

As DNA synthesis technologies mature, the U.S. market is positioned to play a central role in enabling the next generation of genetic innovation. From advancing gene and cell therapies to supporting global health initiatives, the sector is critical to driving precision medicine forward, improving clinical outcomes, and expanding the capabilities of modern life science research.

key Request a free sample copy or view report summary: U.S. DNA Synthesis Market Report

U.S. DNA Synthesis Market Report Highlights

By service type, the oligonucleotide synthesis segment led the U.S. DNA synthesis market in 2024, capturing 55.67%. This leadership is due to the widespread use of synthetic oligonucleotides in molecular biology applications such as PCR, qPCR, gene expression analysis, and CRISPR-based gene editing. Oligonucleotides serve as essential tools in research and clinical diagnostics, and their increasing demand across academic and commercial laboratories continues to propel segment growth.
By application, the research and development (R&D) segment led the market in 2024, capturing 63.82% of the total market share. Researchers across universities, biotech firms, and government labs increasingly rely on DNA synthesis to support fundamental studies in genomics, synthetic biology, and disease modeling. As scientific innovation accelerates, the need for custom, high-fidelity DNA sequences expand, enabling deeper exploration of gene function, cellular pathways, and therapeutic targets. The R&D segment plays a pivotal role in shaping the future of gene-based technologies and translational research.
By end use, biopharmaceutical and diagnostics companies dominated the U.S. DNA synthesis market in 2024, accounting for 49.87% of the total share. These companies are at the forefront of utilizing synthetic DNA in developing gene therapies, nucleic acid-based vaccines, molecular diagnostics, and cell-based treatments. With the growing need for scalable, accurate, and regulatory-compliant synthesis solutions, biopharma firms are increasingly partnering with DNA synthesis providers to accelerate product development and commercialization. The segment's dominance reflects its central role in translating synthetic biology innovations into clinical and commercial applications.
In May 2025, Twist Bioscience and Ginkgo Bioworks (U.S.) revised their collaboration, a three-year, USD 15?million agreement granted Twist long. DNA synthesis IP while Ginkgo retained product supply with flexible ordering.

U.S. DNA Synthesis Market Segmentation

Grand View Research has segmented the U.S. DNA synthesis market on the basis of service type, application, and end use.

U.S. DNA Synthesis Service Type Outlook (Revenue, USD Million, 2021 - 2033)

Oligonucleotide Synthesis
- By Type
  - Standard Oligonucleotide Synthesis
  - Custom Oligonucleotide Synthesis
- By Length
  - Less than 50 nt
  - 51-100 nt
  - 101-150 nt
  - More than 150 nt
Gene Synthesis
- By Type
  - Custom Gene Synthesis
  - Gene Library Synthesis
- By Length
  - Less than 500 nt
  - 501-1000 nt
  - 1001-1500 nt
  - 1501-2000 nt
  - 2001-2500 nt
  - More than 2500 nt

U.S. DNA Synthesis Application Outlook (Revenue, USD Million, 2021 - 2033)

Research and Development
- Oligonucleotide Synthesis
  - PCR
  - NGS
  - CRISPR
  - Cloning and Mutagenesis
  - Others
- Gene Synthesis
  - Synthetic Biology
  - Vaccine Development
  - Genetic Engineering
  - Others
- Diagnostics
- Therapeutics
  - RNAi Therapies
  - Antisense Oligonucleotide-based Therapies
  - Others